View
comments
Pfizer Inc submitted an application with the U.S. Food and Drug Administration for emergency use authorization of its COVID-19 pill on Tuesday.
Recent clinical trial data found the drug can can cut rates of hospitalization and death from the virus by nearly 90 percent.
Additionally, it may become an important tool in cities and countries that have limited access to vaccines or low vaccination rates.
Pfizer CEO Albert Bourla had said earlier today that the company planned to submit data to the FDA before Thanksgiving.
Pfizer submitted its application to the FDA for emergency use authorization of its COVID-19 pill on Tuesday (file image)
Pfizer's candidate, which is called PF-07321332, belongs to a class of drugs known as protease inhibitors.
The pill would work by inhibiting an enzyme that the coronavirus uses to
